search
Back to results

Lean Beef Consumption and Insulin Sensitivity in Men and Women With Risk Factors for Diabetes

Primary Purpose

Metabolic Syndrome, PreDiabetes

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
USDA Style Diet
Lean Beef Diet
Sponsored by
Midwest Center for Metabolic and Cardiovascular Research
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Metabolic Syndrome

Eligibility Criteria

18 Years - 74 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. BMI of 25.0-39.9 kg/m2.
  2. Metabolic syndrome (exhibiting at least 3 out of 5 of the criteria) AND/OR prediabetes (either fingerstick glycated hemoglobin 5.7-6.4%, fasting fingerstick capillary glucose of 100-125 mg/dL, or 2-h post-prandial glucose of 140-199 mg/dL).
  3. Fasting LDL-C level <200 mg/dL and fasting TG level <400 mg/dL.
  4. Willingness to consume only study-related foods/beverages during each test period and consume all of the study foods provided for each day.
  5. Willingness to come to the clinic for study food pick-up as needed.
  6. Judged to be in general good health, aside from the inclusionary metabolic criteria for the study, on the basis of medical history and screening laboratory tests.

Exclusion Criteria:

  1. Atherosclerotic cardiovascular disease including any of the following: clinical signs of atherosclerosis including peripheral arterial disease, abdominal aortic aneurysm, carotid artery disease [symptomatic (e.g., transient ischemic attack or stroke of carotid origin) or >50% stenosis on angiography or ultrasound], history of myocardial infarction, angina, or other forms of clinical atherosclerotic disease (e.g., renal artery disease).
  2. History or presence of clinically important pulmonary (including uncontrolled asthma), endocrine (including type 1 or type 2 diabetes mellitus), chronic inflammatory disease (including irritable bowel disease, lupus, rheumatoid arthritis), hepatic, renal, hematologic, immunologic, dermatologic, neurologic, psychiatric, or biliary disorders.
  3. Known allergy, sensitivity, or intolerance to any ingredients in the study foods (e.g., dairy, nuts, etc.).
  4. Uncontrolled hypertension.
  5. Recent history of cancer except for non-melanoma skin cancer.
  6. Recent change in body weight of ± 4.5 kg (10 lbs).
  7. Unstable use of any antihypertensive medication.
  8. Recent use of medications intended to alter the lipid profile [e.g., bile acid sequestrants, cholesterol absorption inhibitor, fibrates, niacin (drug form), omega-3-ethyl ester drugs, and/or proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors], weight-loss drugs or programs, systemic corticosteroid drugs, medications known to influence carbohydrate metabolism (e.g., adrenergic receptor blockers, diuretics, and/or hypoglycemic medications).
  9. Recent use of foods or dietary supplements known to influence lipid metabolism (e.g., omega-3 fatty acids supplements or fortified foods, sterol/stanol products, red rice yeast supplements, garlic supplements, soy isoflavone supplements, niacin or its analogues at doses >400 mg/d and irregular or inconsistent use of Metamucil® or viscous fiber-containing supplements.
  10. Recent use of antibiotics.
  11. Pregnant, planning to be pregnant during the study period, lactating, or of childbearing potential and unwilling to commit to the use of a medically approved form of contraception throughout the study period.
  12. Extreme dietary habits (e.g., very low carbohydrate diet, vegan, vegetarian, etc.) or unwillingness to consume study foods.
  13. Current or recent history or strong potential for drug or alcohol abuse.
  14. History of a diagnosed eating disorder (e.g., anorexia or bulimia nervosa).
  15. Recent exposure to any non-registered drug product.

Sites / Locations

  • MB Clinical Research, LLC

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

USDA Style Diet

Lean Beef Diet

Arm Description

Healthy, low saturated fat, United States Department of Agriculture (USDA) style diet.

Healthy, low saturated fat, high in lean beef diet.

Outcomes

Primary Outcome Measures

Change in insulin sensitivity index (Si)
Differences in the change from baseline between test conditions (lean beef diet and USDA diet) in the insulin sensitivity index (Si) using the short IVGTT.

Secondary Outcome Measures

Disposition index of pancreatic beta-cell function [Si x acute insulin response to intravenous glucose (AIRg)]
Percent change (or change) from baseline to the end of each test condition.
Fractional glucose disappearance constant from t = 10-50 min (Kg)
Percent change (or change) from baseline to the end of each test condition.
Homeostasis model assessment of beta cell function (HOMA%B) and insulin sensitivity (HOMA%S)
Percent change (or change) from baseline to the end of each test condition.
Insulin sensitivity (HOMA%S)
Percent change (or change) from baseline to the end of each test condition.
Total Cholesterol (TC)
Percent change (or change) in TC from baseline to the end of each test condition
Low-density Lipoprotein Cholesterol (LDL-C)
Percent change (or change) in LDL-C from baseline to the end of each test condition
High-density Lipoprotein Cholesterol (HDL-C)
Percent change (or change) in HDL-C from baseline to the end of each test condition
Non-HDL-C
Percent change (or change) in Non-HDL-C from baseline to the end of each test condition
Triglycerides (TG)
Percent change (or change) in TG from baseline to the end of each test condition
TC/HDL-C ratio
Percent change (or change) in TC/HDL-C ratio from baseline to the end of each test condition
High-sensitivity C-reactive protein (hs-CRP)
Percent change (or change) from baseline to the end of each test condition in levels of hs-CRP
Resting, seated systolic and diastolic blood pressures
Percent change (or change) from baseline to the end of each test condition.
Lipoprotein subfraction and particle concentrations.
Percent change (or change) in lipoprotein subfraction and particle concentrations from baseline to the end of each test condition.
Apo B measurements.
Percent change (or change) in Apo B levels from baseline to the end of each test condition.
Apo A1 measurements.
Percent change (or change) in Apo A1 levels from baseline to the end of each test condition.

Full Information

First Posted
June 26, 2017
Last Updated
July 23, 2019
Sponsor
Midwest Center for Metabolic and Cardiovascular Research
Collaborators
National Cattlemen's Beef Association
search

1. Study Identification

Unique Protocol Identification Number
NCT03202680
Brief Title
Lean Beef Consumption and Insulin Sensitivity in Men and Women With Risk Factors for Diabetes
Official Title
A Randomized, Controlled-Feeding, Crossover Trial to Assess the Effects of Increasing Lean Beef Consumption Within a Healthy Dietary Pattern on Insulin Sensitivity in Men and Women With Risk Factors for Diabetes Mellitus.
Study Type
Interventional

2. Study Status

Record Verification Date
July 2019
Overall Recruitment Status
Completed
Study Start Date
July 6, 2017 (Actual)
Primary Completion Date
July 16, 2018 (Actual)
Study Completion Date
July 16, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Midwest Center for Metabolic and Cardiovascular Research
Collaborators
National Cattlemen's Beef Association

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The objective of this trial is to compare the effects of a healthy, lean beef diet and an average American, United States Department of Agriculture (USDA) style diet, that is low in saturated fatty acids (SFA), on insulin sensitivity in men and women with risk factors for diabetes mellitus.
Detailed Description
This is a randomized, controlled, crossover study that includes two screening visits, one baseline visit, two 28-d test periods and an end-of-washout visit. A 2-week washout period will separate the two treatments. Subjects will be screened to identify metabolic syndrome and/or prediabetes at the screening visits. Eligible subjects will be randomly assigned to a test sequence (USDA/lean beef or lean beef/USDA diets) and the appropriate calorie menu within each test diet, which will be determined based on each subject's calculated energy needs for weight maintenance. Study foods will be dispensed, and subjects will be instructed to consume all of the foods in their entirety for the duration of each 28-d test period, and avoid consuming any additional food or drink items that has not been provided to them. Compliance will be assessed through a Food Deviation Log where subjects will record any non-study food/beverages consumed, and any portions of the study foods not consumed. An intravenous glucose tolerance test (IVGTT) will be completed at baseline and the end of each treatment period, and fasting glucose and insulin will also be measured at screening and at the first test visit in each treatment period. Fasting blood samples will be collected for lipid profile and high-sensitivity C-reactive protein (hs-CRP) measurements at all treatment visits. Additionally, fasting blood will be drawn for measurement of apolipoprotein B and A1 and lipoprotein particles and subfractions at baseline and the end of each treatment period. Assessments of vital signs, body weight, evaluation of inclusion and exclusion criteria, medication/supplement use, and adverse effects will be performed throughout the study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metabolic Syndrome, PreDiabetes

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
49 (Actual)

8. Arms, Groups, and Interventions

Arm Title
USDA Style Diet
Arm Type
Active Comparator
Arm Description
Healthy, low saturated fat, United States Department of Agriculture (USDA) style diet.
Arm Title
Lean Beef Diet
Arm Type
Experimental
Arm Description
Healthy, low saturated fat, high in lean beef diet.
Intervention Type
Other
Intervention Name(s)
USDA Style Diet
Intervention Description
USDA style healthy diet, low in saturated fats.
Intervention Type
Other
Intervention Name(s)
Lean Beef Diet
Intervention Description
A lean beef containing healthy diet, low in saturated fats.
Primary Outcome Measure Information:
Title
Change in insulin sensitivity index (Si)
Description
Differences in the change from baseline between test conditions (lean beef diet and USDA diet) in the insulin sensitivity index (Si) using the short IVGTT.
Time Frame
Up to 50 minutes - measured at baseline, and end of each treatment period.
Secondary Outcome Measure Information:
Title
Disposition index of pancreatic beta-cell function [Si x acute insulin response to intravenous glucose (AIRg)]
Description
Percent change (or change) from baseline to the end of each test condition.
Time Frame
Up to 50 minutes - measured at baseline, and end of each treatment period.
Title
Fractional glucose disappearance constant from t = 10-50 min (Kg)
Description
Percent change (or change) from baseline to the end of each test condition.
Time Frame
Up to 50 minutes - measured at baseline, and end of each treatment period.
Title
Homeostasis model assessment of beta cell function (HOMA%B) and insulin sensitivity (HOMA%S)
Description
Percent change (or change) from baseline to the end of each test condition.
Time Frame
Up to 28 days for each treatment period.
Title
Insulin sensitivity (HOMA%S)
Description
Percent change (or change) from baseline to the end of each test condition.
Time Frame
Up to 28 days for each treatment period.
Title
Total Cholesterol (TC)
Description
Percent change (or change) in TC from baseline to the end of each test condition
Time Frame
Up to 28 days for each treatment period.
Title
Low-density Lipoprotein Cholesterol (LDL-C)
Description
Percent change (or change) in LDL-C from baseline to the end of each test condition
Time Frame
Up to 28 days for each treatment period.
Title
High-density Lipoprotein Cholesterol (HDL-C)
Description
Percent change (or change) in HDL-C from baseline to the end of each test condition
Time Frame
Up to 28 days for each treatment period.
Title
Non-HDL-C
Description
Percent change (or change) in Non-HDL-C from baseline to the end of each test condition
Time Frame
Up to 28 days for each treatment period.
Title
Triglycerides (TG)
Description
Percent change (or change) in TG from baseline to the end of each test condition
Time Frame
Up to 28 days for each treatment period.
Title
TC/HDL-C ratio
Description
Percent change (or change) in TC/HDL-C ratio from baseline to the end of each test condition
Time Frame
Up to 28 days for each treatment period.
Title
High-sensitivity C-reactive protein (hs-CRP)
Description
Percent change (or change) from baseline to the end of each test condition in levels of hs-CRP
Time Frame
Up to 28 days for each treatment period.
Title
Resting, seated systolic and diastolic blood pressures
Description
Percent change (or change) from baseline to the end of each test condition.
Time Frame
Up to 28 days for each treatment period.
Title
Lipoprotein subfraction and particle concentrations.
Description
Percent change (or change) in lipoprotein subfraction and particle concentrations from baseline to the end of each test condition.
Time Frame
Up to 28 days for each treatment period.
Title
Apo B measurements.
Description
Percent change (or change) in Apo B levels from baseline to the end of each test condition.
Time Frame
Up to 28 days for each treatment period.
Title
Apo A1 measurements.
Description
Percent change (or change) in Apo A1 levels from baseline to the end of each test condition.
Time Frame
Up to 28 days for each treatment period.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
74 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: BMI of 25.0-39.9 kg/m2. Metabolic syndrome (exhibiting at least 3 out of 5 of the criteria) AND/OR prediabetes (either fingerstick glycated hemoglobin 5.7-6.4%, fasting fingerstick capillary glucose of 100-125 mg/dL, or 2-h post-prandial glucose of 140-199 mg/dL). Fasting LDL-C level <200 mg/dL and fasting TG level <400 mg/dL. Willingness to consume only study-related foods/beverages during each test period and consume all of the study foods provided for each day. Willingness to come to the clinic for study food pick-up as needed. Judged to be in general good health, aside from the inclusionary metabolic criteria for the study, on the basis of medical history and screening laboratory tests. Exclusion Criteria: Atherosclerotic cardiovascular disease including any of the following: clinical signs of atherosclerosis including peripheral arterial disease, abdominal aortic aneurysm, carotid artery disease [symptomatic (e.g., transient ischemic attack or stroke of carotid origin) or >50% stenosis on angiography or ultrasound], history of myocardial infarction, angina, or other forms of clinical atherosclerotic disease (e.g., renal artery disease). History or presence of clinically important pulmonary (including uncontrolled asthma), endocrine (including type 1 or type 2 diabetes mellitus), chronic inflammatory disease (including irritable bowel disease, lupus, rheumatoid arthritis), hepatic, renal, hematologic, immunologic, dermatologic, neurologic, psychiatric, or biliary disorders. Known allergy, sensitivity, or intolerance to any ingredients in the study foods (e.g., dairy, nuts, etc.). Uncontrolled hypertension. Recent history of cancer except for non-melanoma skin cancer. Recent change in body weight of ± 4.5 kg (10 lbs). Unstable use of any antihypertensive medication. Recent use of medications intended to alter the lipid profile [e.g., bile acid sequestrants, cholesterol absorption inhibitor, fibrates, niacin (drug form), omega-3-ethyl ester drugs, and/or proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors], weight-loss drugs or programs, systemic corticosteroid drugs, medications known to influence carbohydrate metabolism (e.g., adrenergic receptor blockers, diuretics, and/or hypoglycemic medications). Recent use of foods or dietary supplements known to influence lipid metabolism (e.g., omega-3 fatty acids supplements or fortified foods, sterol/stanol products, red rice yeast supplements, garlic supplements, soy isoflavone supplements, niacin or its analogues at doses >400 mg/d and irregular or inconsistent use of Metamucil® or viscous fiber-containing supplements. Recent use of antibiotics. Pregnant, planning to be pregnant during the study period, lactating, or of childbearing potential and unwilling to commit to the use of a medically approved form of contraception throughout the study period. Extreme dietary habits (e.g., very low carbohydrate diet, vegan, vegetarian, etc.) or unwillingness to consume study foods. Current or recent history or strong potential for drug or alcohol abuse. History of a diagnosed eating disorder (e.g., anorexia or bulimia nervosa). Recent exposure to any non-registered drug product.
Facility Information:
Facility Name
MB Clinical Research, LLC
City
Boca Raton
State/Province
Florida
ZIP/Postal Code
33487
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
32359153
Citation
Maki KC, Wilcox ML, Dicklin MR, Buggia M, Palacios OM, Maki CE, Kramer M. Substituting Lean Beef for Carbohydrate in a Healthy Dietary Pattern Does Not Adversely Affect the Cardiometabolic Risk Factor Profile in Men and Women at Risk for Type 2 Diabetes. J Nutr. 2020 Jul 1;150(7):1824-1833. doi: 10.1093/jn/nxaa116.
Results Reference
derived

Learn more about this trial

Lean Beef Consumption and Insulin Sensitivity in Men and Women With Risk Factors for Diabetes

We'll reach out to this number within 24 hrs